DANAHER CORP /DE/ (DHR) Form 10-Q — Oct 20, 2026
Danaher's Q3 2026 revenue rose 8.5% to $6.55 billion, with core sales up 3.0% (5.5% ex-respiratory testing), and diluted EPS from continuing operations jumped to $1.71 from $1.27 a year ago. However, $263 million of discrete tax benefits from audit settlements drove much of the earnings increase; nine-month operating profit grew more modestly to $3.7 billion from $3.2 billion. The quarter's balance sheet reflects the $9.8 billion Masimo acquisition completed June 10, 2026, funded with new Euro and Swiss franc debt that lifted total borrowings to $26.5 billion from $18.4 billion at year-end. Danaher also closed the $1.4 billion StatLab acquisition on September 28, 2026.
Key figures
- Eps
- 1.71
- Revenue
- 6554000000
- Net Income
- 1235000000
- Total Debt
- 26482000000
- Total Assets
- 93281000000
- Cash Position
- 5682000000
- Goodwill balance
- $47,315 million
- Nine month revenue
- 18770000000
- Statlab acquisition
- $1.4 billion (September 28, 2026)
- Core sales growth q3
- 3.0%
- Masimo purchase price
- $9.8 billion ($180.00 per share)
- Shares outstanding oct 15 2026
- 703530815
- Nine month diluted eps continuing
- 4.38
- Core sales growth ex respiratory q3
- 5.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.